<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534884</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P10 1.1</org_study_id>
    <secondary_id>2011-002822-37</secondary_id>
    <nct_id>NCT01534884</nct_id>
  </id_info>
  <brief_title>Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>Triad RA</acronym>
  <official_title>Phase 1, Randomized, Controlled, Multicenter, 2-Arm, Parallel-Group, Double-Blind Study to Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized,controlled, multicenter, 2-arm, parallel-group, double-blind, prospective,
      Phase 1 study is designed to demonstrate comparable pharmacokinetics in terms of AUC0-last
      and Cmax (after second infusion) between CT-P10 and MabThera in patients with active RA
      concomitantly treated with MTX during the Core Study Period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK in terms of Cmax</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>maximum serum concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>MabThera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-P10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.</description>
    <arm_group_label>MabThera</arm_group_label>
    <arm_group_label>CT-P10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has a diagnosis of RA according to the revised 1987 ACR classification
             criteria (Arnett et al 1987) for at least 6 months prior to randomization.

          2. Patient has active disease as defined by the presence of 6 or more swollen joints (of
             66 assessed) and 6 or more tender joints (of 68 assessed), and serum CRP ≥1.5 mg/dL or
             an ESR ≥28 mm/hour.

        Exclusion Criteria:

          1. Patient is unresponsive or intolerable to more than 2 biologic agents.

          2. Patient has allergies or hypersensitivity to murine, chimeric, human, or humanized
             proteins.

          3. Patient has current or past history of chronic infection with hepatitis B, hepatitis
             C, or infection with human immunodeficiency virus (HIV)-1 or -2 or who has a positive
             result to the screening test for these infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DaeHyun Yoo, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2012</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RA, Biosimilar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

